08:00 , Jan 15, 2015 |  BC Innovations  |  Tools & Techniques

Boosting IgG with IgA

Although all marketed therapeutic mAbs use an IgG backbone, mostly for pharmacokinetic reasons, the antibodies don't do a good job of inducing neutrophils to kill cancer cells. A group at the University of Texas at...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Chimeric IgG-IgA Fc domains

Drug platforms TECHNOLOGY: Antibody scaffolds Antibodies and Fc fusion proteins engineered with chimeric IgG-IgA Fc domains could be more effective than therapeutics with IgG Fc domains. A chimeric Fc domain was engineered that possesses biological activities of...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Pikamab, University of Alabama at Birmingham Research Foundation deal

Pikamab received exclusive rights to the foundation's U.S. Patent No. 6,986,987, which covers the role of the functional polymorphism (Ser/Gly-248) in the cytoplasmic domain of CD89 (Fc alpha receptor type 1) in IgA-mediated autoimmune...